Hematology/Oncology News

The rates of melanoma incidence have significantly declined since approximately 2015 in patients aged younger than 50 years while mortality also dropped in those aged younger than 60, according to a Swedish study.

Although progress has been made, lack of diversity continues to be problematic in trials of immune checkpoint inhibitors, according to study results.

Researchers have found evidence that the contents of an individual’s oral microbiome may be associated with their risk for head and neck cancers.

A simple blood test that measures lymphocyte count may accurately predict response to chimeric antigen receptor T-cell therapy among patients with relapsed multiple myeloma, according to study results.

In this interview, Naval Daver, MD, discusses a session on myelodysplastic syndrome from Society of Hematologic Oncology Annual Meeting.

Enzalutamide conferred small but statistically significant improvements in outcomes vs. abiraterone acetate for men with metastatic castration-resistant prostate cancer, according to retrospective study results.

Naval Daver, MD, spoke with Healio about updates in FLT3-mutated acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.

Zyno Medical is recalling select Z800 infusion pumps due to a defect in the air-in-line software algorithm that may allow a 1 mL air bubble to be passed on to a patient, according to the FDA.

The FDA approved marstacimab-hncq for treatment of certain individuals with hemophilia.

Bluebird Bio’s lentiviral vector gene therapy Skysona met its primary efficacy endpoint of survival without major functional disability in 81% of boys with early cerebral adrenoleukodystrophy, a recent analysis showed.